Solagran Limited Announces Pricing For Ropren Outside Russia

Melbourne, Aug 15, 2007 (ACN Newswire) - Melbourne based Biotech Solagran Limited (ASX: SLA) today announced that arrangements were being put in place in St Petersburg to supply patients outside Russia with its liver disease drug Ropren, consistent with international regulatory guidelines.

MORE ON THIS TOPIC